Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes

類似資料

• Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
  著者:: Schoenfeld, Adam J., 等
  出版事項: (2020)
• Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.
  著者:: Offin, Michael, 等
  出版事項: (2018)
• Lineage plasticity in cancer: a shared pathway of therapeutic resistance
  著者:: Quintanal-Villalonga, Álvaro, 等
  出版事項: (2020)
• Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
  著者:: Yu, H. A., 等
  出版事項: (2014)
• Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions
  著者:: Choudhury, Noura J., 等
  出版事項: (2021)